qiaseq mouse tcr sequencing kit Search Results


qiaseq mouse tcr sequencing kit #333705  (Qiagen)
90
Qiagen qiaseq mouse tcr sequencing kit #333705
Transcriptomic and <t>TCR</t> repertoire analysis of the samples from mice treated with BF10 versus its subcomponents (A) An illustration of mice receiving the indicated treatment followed by tumor isolation for bulk RNA-seq and gene set enrichment analysis (GSEA). (B–F) Enrichment plots of genes sets in BF10 versus control in mouse tumor samples. Significant pathways were identified by GSEA gene set of IFN-γ response (B), IFN-α response (C), inflammatory response (D), complement (E), and genes upregulated in CD8 T cells (GEO: GSE41867 ) (F). (G) The heatmap of GSEA enriched pathways in treatment groups. The normalized enrichment score (NES) and p value are shown. (H) Schema of bioinformatic strategy to study the effect of BF10 within tumor microenvironment. Tumors derived from two syngeneic tumor models (HNSC/Q1-2 and BRCA/4T1) treated with BF10, IL-10-Fc, αCSF-1R, or control were collected for bulk RNA-seq to investigate the differentially expressed genes (DEGs; >1.5-fold and p < 0.05 or <0.5-fold and p < 0.05). DEGs were analyzed using 2 modules: (1) Bioinformatics Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov/ ) and (2) Ingenuity Pathway Analysis (IPA). (I) DAVID functional Gene Ontology analysis. (J) IPA. (K) Immune repertoire TCR <t>sequencing</t> of CD8 + T cells. Tumor-bearing mice received treatments of Ctrl-IgG, IL-10, anti-CSF1R, or BF10 for 3 doses, followed by RNA extraction of isolated CD8 + T cells for TCR immune repertoire analysis. The data are shown as clonotype diversity and distribution of both TRAC and TRBC CDR3 sequencing from tumor and spleen. The number of the bracket indicates observed diversity in the enrichment metrics of <t>QIAseq-RNA</t> Immune Repertoire Application. (L) Examination of the TCR immune repertoire using Morisita-Horn index.
Qiaseq Mouse Tcr Sequencing Kit #333705, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qiaseq mouse tcr sequencing kit #333705/product/Qiagen
Average 90 stars, based on 1 article reviews
qiaseq mouse tcr sequencing kit #333705 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
qiaseq mouse tcr sequencing kit  (Qiagen)
90
Qiagen qiaseq mouse tcr sequencing kit
Transcriptomic and <t>TCR</t> repertoire analysis of the samples from mice treated with BF10 versus its subcomponents (A) An illustration of mice receiving the indicated treatment followed by tumor isolation for bulk RNA-seq and gene set enrichment analysis (GSEA). (B–F) Enrichment plots of genes sets in BF10 versus control in mouse tumor samples. Significant pathways were identified by GSEA gene set of IFN-γ response (B), IFN-α response (C), inflammatory response (D), complement (E), and genes upregulated in CD8 T cells (GEO: GSE41867 ) (F). (G) The heatmap of GSEA enriched pathways in treatment groups. The normalized enrichment score (NES) and p value are shown. (H) Schema of bioinformatic strategy to study the effect of BF10 within tumor microenvironment. Tumors derived from two syngeneic tumor models (HNSC/Q1-2 and BRCA/4T1) treated with BF10, IL-10-Fc, αCSF-1R, or control were collected for bulk RNA-seq to investigate the differentially expressed genes (DEGs; >1.5-fold and p < 0.05 or <0.5-fold and p < 0.05). DEGs were analyzed using 2 modules: (1) Bioinformatics Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov/ ) and (2) Ingenuity Pathway Analysis (IPA). (I) DAVID functional Gene Ontology analysis. (J) IPA. (K) Immune repertoire TCR <t>sequencing</t> of CD8 + T cells. Tumor-bearing mice received treatments of Ctrl-IgG, IL-10, anti-CSF1R, or BF10 for 3 doses, followed by RNA extraction of isolated CD8 + T cells for TCR immune repertoire analysis. The data are shown as clonotype diversity and distribution of both TRAC and TRBC CDR3 sequencing from tumor and spleen. The number of the bracket indicates observed diversity in the enrichment metrics of <t>QIAseq-RNA</t> Immune Repertoire Application. (L) Examination of the TCR immune repertoire using Morisita-Horn index.
Qiaseq Mouse Tcr Sequencing Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qiaseq mouse tcr sequencing kit/product/Qiagen
Average 90 stars, based on 1 article reviews
qiaseq mouse tcr sequencing kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Transcriptomic and TCR repertoire analysis of the samples from mice treated with BF10 versus its subcomponents (A) An illustration of mice receiving the indicated treatment followed by tumor isolation for bulk RNA-seq and gene set enrichment analysis (GSEA). (B–F) Enrichment plots of genes sets in BF10 versus control in mouse tumor samples. Significant pathways were identified by GSEA gene set of IFN-γ response (B), IFN-α response (C), inflammatory response (D), complement (E), and genes upregulated in CD8 T cells (GEO: GSE41867 ) (F). (G) The heatmap of GSEA enriched pathways in treatment groups. The normalized enrichment score (NES) and p value are shown. (H) Schema of bioinformatic strategy to study the effect of BF10 within tumor microenvironment. Tumors derived from two syngeneic tumor models (HNSC/Q1-2 and BRCA/4T1) treated with BF10, IL-10-Fc, αCSF-1R, or control were collected for bulk RNA-seq to investigate the differentially expressed genes (DEGs; >1.5-fold and p < 0.05 or <0.5-fold and p < 0.05). DEGs were analyzed using 2 modules: (1) Bioinformatics Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov/ ) and (2) Ingenuity Pathway Analysis (IPA). (I) DAVID functional Gene Ontology analysis. (J) IPA. (K) Immune repertoire TCR sequencing of CD8 + T cells. Tumor-bearing mice received treatments of Ctrl-IgG, IL-10, anti-CSF1R, or BF10 for 3 doses, followed by RNA extraction of isolated CD8 + T cells for TCR immune repertoire analysis. The data are shown as clonotype diversity and distribution of both TRAC and TRBC CDR3 sequencing from tumor and spleen. The number of the bracket indicates observed diversity in the enrichment metrics of QIAseq-RNA Immune Repertoire Application. (L) Examination of the TCR immune repertoire using Morisita-Horn index.

Journal: Cell Reports Medicine

Article Title: A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8 + T cells

doi: 10.1016/j.xcrm.2023.101154

Figure Lengend Snippet: Transcriptomic and TCR repertoire analysis of the samples from mice treated with BF10 versus its subcomponents (A) An illustration of mice receiving the indicated treatment followed by tumor isolation for bulk RNA-seq and gene set enrichment analysis (GSEA). (B–F) Enrichment plots of genes sets in BF10 versus control in mouse tumor samples. Significant pathways were identified by GSEA gene set of IFN-γ response (B), IFN-α response (C), inflammatory response (D), complement (E), and genes upregulated in CD8 T cells (GEO: GSE41867 ) (F). (G) The heatmap of GSEA enriched pathways in treatment groups. The normalized enrichment score (NES) and p value are shown. (H) Schema of bioinformatic strategy to study the effect of BF10 within tumor microenvironment. Tumors derived from two syngeneic tumor models (HNSC/Q1-2 and BRCA/4T1) treated with BF10, IL-10-Fc, αCSF-1R, or control were collected for bulk RNA-seq to investigate the differentially expressed genes (DEGs; >1.5-fold and p < 0.05 or <0.5-fold and p < 0.05). DEGs were analyzed using 2 modules: (1) Bioinformatics Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov/ ) and (2) Ingenuity Pathway Analysis (IPA). (I) DAVID functional Gene Ontology analysis. (J) IPA. (K) Immune repertoire TCR sequencing of CD8 + T cells. Tumor-bearing mice received treatments of Ctrl-IgG, IL-10, anti-CSF1R, or BF10 for 3 doses, followed by RNA extraction of isolated CD8 + T cells for TCR immune repertoire analysis. The data are shown as clonotype diversity and distribution of both TRAC and TRBC CDR3 sequencing from tumor and spleen. The number of the bracket indicates observed diversity in the enrichment metrics of QIAseq-RNA Immune Repertoire Application. (L) Examination of the TCR immune repertoire using Morisita-Horn index.

Article Snippet: The same amount RNA (100 ng and RIN >8) of indicated group was applied to construct RNA-seq libraries using QIAseq Mouse TCR Sequencing kit (#333705, Qiagen).

Techniques: Isolation, RNA Sequencing, Control, Derivative Assay, Functional Assay, Sequencing, RNA Extraction

Journal: Cell Reports Medicine

Article Title: A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8 + T cells

doi: 10.1016/j.xcrm.2023.101154

Figure Lengend Snippet:

Article Snippet: The same amount RNA (100 ng and RIN >8) of indicated group was applied to construct RNA-seq libraries using QIAseq Mouse TCR Sequencing kit (#333705, Qiagen).

Techniques: Control, Flow Cytometry, RNA Sequencing, Sequencing, Recombinant, Labeling, Enzyme-linked Immunosorbent Assay, Binding Assay, Polymer, Cell Isolation, Selection, Software